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Abstract
Rationale Maladaptive impulsivity is symptomatic of several neuropsychiatric disorders including schizophrenia, attention-
deficit hyperactivity disorder (ADHD), and substance abuse disorders; paradigms designed to assess the underlying neurobiology
of this behavior are essential for the discovery of novel therapeutic agents. Various models may be used to assess impulsivity as
measured by the five-choice serial reaction time task (5-CSRTT), including variable inter-trial interval (ITI) sessions, the
selection of extreme high and low impulsivity phenotypes from a large outbred population of rats, as well as pharmacological
challenges.
Objectives The aim of this study is to evaluate if pharmacological challenge models for impulsivity are biased by underlying
differences in impulsivity phenotype.
Methods Extreme high and low impulsivity phenotypes were selected in the 5-CSRTT, and dose-dependent effects of various
pharmacological challenges, namely MK-801, yohimbine, and cocaine, were evaluated on task performance, specifically accu-
racy and premature responses.
Results All three compounds increased premature responding, while a decrease in attentional performance occurred following
MK-801 and yohimbine administration. No differences in drug-induced impulsivity between rats selected for high or low
impulsivity or in parameters indicative of attentional performance could be determined.
Conclusions Our findings indicate that different pharmacological challenges increase impulsivity on the 5-CSRTT, with modest
effects on attention. These effects were not influenced by underlying differences in impulsivity phenotype, which is an important
prerequisite to reliably use these challenge models to screen and profile compounds with putative anti-impulsive characteristics.
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Introduction
Impulsivity is a complex, multifaceted behavioral construct,
characterized by the tendency to act prematurely and without
foresight (Dalley et al. 2011). It can be observed behaviorally
as impaired response inhibition or the inability to tolerate de-
layed rewards. Maladaptive impulsivity is symptomatic of
several neuropsychiatric disorders including schizophrenia
(Heerey et al. 2007; Kaladjian et al. 2011), attention-deficit
hyperactivity disorder (ADHD) (Schachar et al. 1995;
Winstanley et al. 2006), and substance abuse disorders
(Ersche et al. 2010). Additionally, there is evidence that im-
puls iv i ty could be regarded as an inte rmedia te
endophenotype; patients with substance abuse disorders show
increased levels of impulsivity on self-report questionnaires
compared with healthy controls, but of particular interest is
that their non-drug-taking siblings also show increased levels
of impulsivity (Ersche et al. 2010). As such, evaluating and
understanding the underlying neural basis of this behavior is
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important to identify novel drugs for the effective treatment of
these disorders.
Behavioral challenges are frequently used on the five-
choice serial reaction time task (5-CSRTT) as a means of
stratifying rats according to their performance. The flexibility
inherent in the task allows the experimenter to manipulate
the exact timing of the stimulus presentation: to make the
waiting period, or inter-trial interval (ITI), short, long, or
unpredictable (Bari et al. 2008). Such manipulations allow
for the study of natural variation in behavior and how this is
related to normal variation in neurotransmitter function,
which may be a more translational approach; however, they
also introduce a number of difficulties. The selection of ex-
treme phenotypes on the 5-CSRTT using extended ITI ses-
sions requires a large number of animals in order to gain an
experimentally useful number of high and low impulsivity
subjects (Bari et al. 2008; Dalley et al. 2007), thus making
this approach impartible when aiming to determine the ef-
fects of drugs and establish the pharmacokinetic-
pharmacodynamic relationship in rats with selected high
and low impulsivity phenotypes. Additionally, variable ITI
sessions require extended testing sessions in order to reach a
statistically useful number of trials for each ITI. As such,
pharmacologically induced challenges may represent a sim-
pler model of maladaptive impulsivity, especially in the con-
text of drug testing and/or modeling specific circuit
malfunctions. There is a plethora of evidence that suggests
maladaptive impulsivity may arise due to dysfunctional in-
teractions within the frontostriatal circuit. Initially, it was
thought that dysfunction in the inhibitory process was mod-
ulated via top-down control mechanisms at the level of the
prefrontal cortex (Aron et al. 2003; Rieger et al. 2003).
However, it is now known that dysfunction at the level of
the basal ganglia and midbrain can also result in extreme
impulsivity phenotypes. Patients with cortical and basal gan-
glia damage show impaired behavioral inhibition compared
with healthy controls (Agnoli and Carli 2012; Dalley et al.
2011), and recent evidence shows dopamine dysfunction
within the midbrain of impulsive individuals (Cole et al.
2013; Ray et al. 2012). It is therefore unsurprising that phar-
macological agents that disrupt transmission within this cir-
cuitry can be used to induce impulsivity on a number of
behavioral tasks.
Impulsive behavior is subject tomodulation by a number of
neurotransmitters and neuromodulators; the most widely ex-
amined include dopamine (DA), serotonin (5-HT), and nor-
adrenaline (NA). Drugs that block the reuptake of DA and
NA, such as methylphenidate or atomoxetine, show clinical
efficacy in the treatment of ADHD. Recently, there has been
an increase in studies examining the contribution of other
neurotransmitters to the regulation of impulsive behavior.
Systemic or directed administration of N-methyl-D-aspartate
(NMDA) receptor antagonists , such as MK-801,
phencyclidine (PCP), and 3-(2-carboxypiperazine-4-
yl)propyl-1-phosphoric acid (CPP), enhance impulsivity on
the 5-CSRTT (Fletcher et al. 2011; Greco et al. 2005;
Mirjana et al. 2004).
In this paper, we confirm that a number of drugs that di-
rectly or indirectly affect dopaminergic neurotransmission
within frontostriatal circuitry (MK-801, an NMDA receptor
antagonist; yohimbine, an α2 adrenoceptor antagonist; and
cocaine) can be used to induce impulsivity on the 5-CSRTT,
and furthermore, that none of these pharmacological chal-
lenges are biased by underlying variations in trait impulsivity.
We believe these data further highlight the advantages of a
drug challenge approach in interrogating the underlying neu-
robiology of impulsive behavior, compared with behavioral
challenges such as extended or variable ITI sessions.
Materials and methods
Subjects
Ninety-sixmale Lister hooded rats, weighing 200–250 g at the
start of training, were obtained from Charles River (Sulzfeld,
Germany) and assessed for performance on the 5-CSRTT. All
rats were housed in groups of four with food and water initial-
ly available ad libitum. All rats were permitted at least 5 days
acclimatization before training on the 5-CSRTT. Food restric-
tion was initiated when body weight was ≥ 300 g. Body
weight was then maintained at 80–85% of free-feeding
weight. All experimental procedures were authorized by the
Local Animal Care and Use Committee and carried out ac-
cording to the local animal care guidelines, AAALAC regu-
lations, and the USDA Animal Welfare Act.
5-CSRTT
Thirty-two five-choice operant chambers (Med Associates
Inc., St. Albans, USA) enclosed in sound-attenuating, fan-
ventilated cubicles were used, as described previously (Bari
et al. 2008; Carli et al. 1983). Briefly, each chamber com-
prised five evenly spaced apertures (2.5 × 2.5 × 4 cm) con-
taining an LED light set into a curved wall at the rear of the
chamber. A centrally located food magazine was located on
the opposite wall of the chamber, into which 45 mg of re-
ward pellets could be delivered (Sandown Scientific).
Infrared beams located at the entrance of each aperture and
the food magazine allowed detection of nose pokes. Task
parameters and data collection were controlled by Med
Associates Inc. software (St. Albans, USA).
The 5-CSRTT training protocol has been described previ-
ously (Isherwood et al. 2015, 2017). Each training session
comprised 100 discrete trials and lasted up to 30 min. At later
training stages, 100 trials were normally completed within
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20 min. Training sessions were initiated by the illumination of
the house light and magazine light and the delivery of reward
pellets. Collection of the reward initiated the first trial. A sin-
gle trial comprised an ITI followed by the pseudo-random
illumination of one of the five apertures for a fixed duration
(stimulus duration; SD). Following stimulus detection, a nose
poke to the corresponding aperture within a fixed time interval
(limited hold; LH) was required for reward delivery.
Premature responses made during the ITI, incorrect responses,
and responses made outside the LH (an omission) were
punished with a timeout (TO), where the house light was
extinguished for 5 s.
Premature responding was calculated as a percentage of
completed trials (correct + incorrect + omissions). A prema-
ture response was deemed an incomplete trial and reset the
current trial. Percentage accuracy was defined as the number
of correct responses divided by the sum of correct and incor-
rect responses. Perseveration was calculated as the number of
additional responses made in the same aperture following a
correct response. Percentage omissions were calculated in
terms of the number of completed trials.
Animals were deemed to be trained when they completed
≥ 50 correct trials, with ≥ 70% accuracy, and ≤ 20% omis-
sions with an SD of 0.7 s, an ITI of 5 s, and a LH of 5 s. At
this stage, perseverative responses (additional responses
made to the same aperture following a correct response) were
also punished with a 5 s TO and loss of food reward. The
range to reach the final stage of task acquisition was 26–38
sessions.
Impulsivity screening
Screening for impulsivity consisted of three Bchallenge^ train-
ing sessions where the ITI was extended to 7 s to increase the
occurrence of premature responses (Dalley et al. 2007). Each
challenge session was separated by four baseline training ses-
sions, during which task parameters were restored to the train-
ing configuration (5 s ITI). The mean percentage of premature
responses made by each rat across the challenge sessions was
calculated. Those with a poor or unstable performance, or that
did not complete 100 trials on 3 challenge sessions, were
excluded from the study (n = 4).
All remaining 92 rats were ranked, from high to low im-
pulsive, based on the mean percentage of premature re-
sponses. The upper and lower 15th centiles of premature re-
sponders were termed high impulsive (HI, n = 13) and low
impulsive (LI, n = 12), respectively. The remaining rats were
termed mid impulsive (MI, n = 67).
Drugs
Drugs were administered according to a randomized Latin
square design. (+)-MK-801 hydrogen maleate and cocaine
hydrochloride were purchased from Sigma Aldrich
(Germany), and yohimbine hydrochloride was purchased
from TCI Deutschland GmbH (Eschborn, Germany). The
dose range and pre-treatment time were selected based on
previous experience (Isherwood et al. 2015), in-house phar-
macokinetic data, and published literature (Fletcher et al.
2011). Since a fully automated data acquisition system was
used, the experimenter was not blinded to treatment. MK-801
was administered via subcutaneous injection, while yohim-
bine and cocaine were administered intraperitoneally. All
drugs were administered in a volume of 1 ml/kg in
phosphate-buffered saline (pH 7.4) using the dose of 0, 0.03,
0.06, 0.1 mg/kg for the MK-801 study; 0, 0.5, 1, 1.5, 2 mg/kg
for the yohimbine study; and 0, 5, 7.5, 10 mg/kg for the co-
caine study. Drugs were administered 10 min before the start
of the behavioral test with a 5-s ITI. Injections were given on a
3-day cycle, starting with a baseline retention session. On the
following day, injections were given prior to testing, and on
the third day animals were not tested and remained in their
home cage. After testing of yohimbine, two low-impulsive
rats were excluded from further drug testing and euthanized
due to poor health status. After testing of cocaine but before
testing of MK-801, another low-impulsive rat and one high-
impulsive rat were excluded due to their health status.
Data analysis
Data were analyzed using SPSS version 21 and GraphPad 6;
the latter software was used to create the figures. Repeated
measures analysis of variance (ANOVA) with appropriate
within- and between-subject factors was used to assess behav-
ioral data. In case of a violation of sphericity, as shown by
significant main effects in Mauchly’s test of sphericity, the
Greenhouse-Geisser correction to the degrees of freedom
was used to correct the p values. Where significant main ef-
fects or interactions were indicated, post-hoc analysis using
Dunnett’s test was performed. Statistical significance was set
at p < 0.05.
Results
Selection of HI and LI rats
Rats were stratified according to their levels of trait impulsiv-
ity, as measured by premature responses across three 7 s ITI
challenge sessions. In this cohort, the frequency of premature
responses was significantly non-normal (W(92) = 0.97,
p < 0.05) and transformation of the data had no effect on the
distribution (Fig. 1a). The rats were segregated into three
groups according to their premature responding: (i) low im-
pulsivity (lower 15%, n = 12); (ii) mid impulsivity (n = 67);
and (iii) high impulsivity (upper 15%, n = 13) (Fig. 1b).
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Effect of yohimbine administration on 5-CSRTT
performance in HI and LI rats
Due to a software issue, no behavioral values were re-
corded for one low-impulsive subject at the 0.5 mg/kg
dose level. For statistical analysis, the missing values
were replaced with the group mean. Yohimbine produced
a significant dose-dependent enhancement of impulsivity,
as reflected by an increase in premature responding
(F(4,92) = 4.271, p < 0.014; Fig. 2a). Post-hoc tests re-
vealed that all three doses of yohimbine significantly in-
creased premature responding compared with vehicle
treatment (0.5 mg/kg, p < 0.01; 1 mg/kg, p < 0.01;
1.5 mg/kg, p < 0.01; 2 mg/kg, p < 0.05). However, no sig-
nificant dose × group interaction was observed (F(4,92) =
2.044, p = 0.131; Fig. 2d). This was accompanied by a
decrease in accuracy of performance (F(4,92) = 5.736, p =
0.001; Fig. 2b) and an increase in omissions (F(4,92) =
4.241, p = 0.009; Fig. 2c). As with premature responses,
no significant dose × group interaction was observed for
either behavioral measure (F(4,92) = 0.354, p = 0.841;
F(4,92) = 1.65, p = 0.188; Fig. 2e, f). Yohimbine produced
modest effects on response latencies and did not affect
perseverative responses (Table 1).
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Fig. 1 aResults from phenotypic screening, data presented as mean ± SD
per daily screening session for high- (n = 13), mid- (n = 77), and low-
impulsive (n = 12) rats. b Frequency distribution of premature
responses, average across three 7 s ITI challenge sessions (n = 92),
fitted with a unimodal Gaussian curve. Skewness = 0.54; kurtosis =
0.21; mean = 52.86; standard deviation = 20.17; median = 52.0;
interquartile range = 21.75. HI high impulsive, MI mid impulsive, LI
low impulsive
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Fig. 2 Effect of yohimbine (n = 25) on a percentage premature responses,
b percentage accuracy, and c percentage omissions. Panels d–f depict the
results when the group is split into low (n = 12) and high (n = 13)
impulsive subjects. Data are mean ± SD. Asterisks denote a significant
difference between the doses indicated: *p < 0.05 and **p < 0.01.HI high
impulsive, LI low impulsive
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Effect of cocaine administration on 5-CSRTT
performance in HI and LI rats
Following yohimbine administration, two low-impulsive
rats were euthanized due to poor health status, resulting
in n = 10 low-impulsive rats and n = 13 high-impulsive rats
for subsequent drug testing. Cocaine produced a signifi-
cant dose-dependent enhancement of impulsivity, as
reflected by an increase in premature responding
(F(3,63) = 5.763, p = 0.005; Fig. 3a). Post-hoc tests revealed
that all three doses of cocaine significantly increased pre-
mature responding compared with vehicle treatment
(5 mg/kg, p < 0.01; 7.5 mg/kg, p < 0.01; 10 mg/kg,
p < 0.05). However, no significant dose × group interaction
was observed (F(3,63) = 0.473, p = 0.646; Fig. 3d). This was
not accompanied by a decrease in accuracy (F(3,63) = 0.868,
p = 0.462; Fig. 3c) or an increase in omissions (F(3,63) =
1.549, p = 0.211; Fig. 3c). Cocaine produced modest ef-
fects on response latencies and did not affect perseverative
responses (Table 1).
Table 1 The effect of yohimbine, cocaine, and MK-801 of high- and low-impulsive rats on 5-CSRTT [correct latency, incorrect latency, reward
latency, number of perseverative responses]
Drug/Response Concentration (mg/kg)
Yohimbine 0 0.5 1 1.5 2
HI
Correct latency (s) 0.675 ± 0.092 0.645 ± 0.092 0.637 ± 0.094 0.662 ± 0.118 0.714 ± 0.125
Incorrect latency (s) 1.288 ± 0.456 1.301 ± 0.326 1.033 ± 0.189 0.944 ± 0.497* 1.364 ± 0.479
Reward latency (s) 1.198 ± 0.148 1.545 ± 0.873 1.220 ± 0.243 1.282 ± 0.228 1.375 ± 0.158**
Perseverative responses (n) 1.231 ± 1.092 3.462 ± 5.840 1.000 ± 1.414 1.538 ± 0.877 1.615 ± 1.557
LI
Correct latency (s) 0.828 ± 0.163 0.751 ± 0.120 0.674 ± 0.090* 0.716 ± 0.122 0.704 ± 0.097*
Incorrect latency (s) 2.008 ± 0.531 1.578 ± 0.435 1.245 ± 0.380* 1.383 ± 0.503 1.331 ± 0.340*
Reward latency (s) 1.216 ± 0.100 1.313 ± 0.228 1.192 ± 0.073 1.197 ± 0.083 1.268 ± 0.112
Perseverative responses (n) 1.333 ± 1.435 1.364 ± 1.367 1.500 ± 1.508 1.417 ± 1.165 1.083 ± 1.505
Cocaine 0 5 7.5 10
HI
Correct latency (s) 0.645 ± 0.101 0.575 ± 0.104 0.563 ± 0.336 0.681 ± 0.334
Incorrect latency (s) 1.372 ± 0.389 0.962 ± 0.390 1.095 ± 0.609 0.959 ± 0.722
Reward latency (s) 1.365 ± 0.620 1.388 ± 0.344 1.238 ± 0.649 1.659 ± 0.851
Perseverative responses (n) 1.846 ± 2.544 1.385 ± 1.609 2.000 ± 3.488 1.692 ± 2.323
LI
Correct latency (s) 0.788 ± 0.146 0.692 ± 0.157 0.717 ± 0.173 0.454 ± 0.264**
Incorrect latency (s) 1.904 ± 0.484 1.562 ± 0.437 1.229 ± 0.893 0.986 ± 0.707*
Reward latency (s) 1.323 ± 0.162 1.562 ± 0.437 1.485 ± 0.404 1.331 ± 0.918
Perseverative responses (n) 1.300 ± 1.337 1.100 ± 1.370 0.500 ± 1.269 0.700 ± 0.823
MK-801 0 0.01 0.03 0.1
HI
Correct latency (s) 0.671 ± 0.082 0.591 ± 0.091 0.739 ± 0.150 0.753 ± 0.152
Incorrect latency (s) 1.297 ± 0.461 1.203 ± 0.452 1.285 ± 0.225 1.856 ± 0.513*
Reward latency (s) 1.193 ± 0.098 1.085 ± 0.142** 1.332 ± 0.442 1.641 ± 0.421**
Perseverative responses (n) 2.667 ± 1.614 2.083 ± 2.503 3.000 ± 2.594 4.083 ± 3.579
LI
Correct latency (s) 0.829 ± 0.119 0.674 ± 0.132** 0.730 ± 0.110 0.753 ± 0.314
Incorrect latency (s) 1.969 ± 0.488 1.391 ± 0.543 1.379 ± 0.449* 1.810 ± 0.691
Reward latency (s) 1.367 ± 0.346 1.144 ± 0.220** 1.207 ± 0.177 1.360 ± 0.572
Perseverative responses (n) 1.556 ± 1.236 1.444 ± 1.590 3.222 ± 2.863 4.556 ± 2.744
5-CSRTT five-choice serial reaction time task, ANOVA analysis of variance, HI high impulsive, LI low impulsive, SD standard deviation
Values represent mean ± SD. Repeated measures ANOVA, Dunnett’s post-hoc test (*p < 0.05, **p < 0.01 versus vehicle control)
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Effect of MK-801 administration on 5-CSRTT
performance in HI and LI rats
Following cocaine administration, a further low-impulsive rat
and one high-impulsive rat were excluded due to their health
status, resulting in n = 9 low-impulsive rats and n = 12 high-
impulsive rats for subsequent drug testing. MK-801 produced
a significant dose-dependent enhancement of impulsivity, as
reflected by an increase in premature responding (F(3,57) =
6.092, p < 0.007; Fig. 4a). Post-hoc tests revealed that all three
doses of MK-801 significantly increased premature
responding compared with vehicle treatment (0.03 mg/kg,
p < 0.01; 0.06 mg/kg, p < 0.01; 0.1 mg/kg, p < 0.05).
However, no significant dose × group interaction was ob-
served (F(3,57) = 0.73, p = 0.474; Fig. 4d). This was accompa-
nied by a decrease in accuracy of performance (F(3,57) =
17.474, p < 0.001; Fig. 4b) and an increase in omissions
(F(3,57) = 46.725, p < 0.001; Fig. 4c). As with premature re-
sponses, no significant dose × group interaction was observed
for either behavioral measure (F(3,57) = 0.673, p = 0.491;
F(3,57) = 0.154, p = 0.747; Fig. 4e, f). MK-801 produced mod-
est effects on response latencies and did not affect persevera-
tive responses (Table 1).
Discussion
The 5-CSRTT is a widely used task to assess attention and
aspects of behavioral inhibition. Here, we outline its use as a
task of impulse control and detail the specific task manipula-
tion that can be used to study both trait and induced
impulsivity. Specifically, we emphasize the utility of pharma-
cological models in studying extreme impulsive behavior. We
show that pharmacological challenges used to induce impul-
sivity, namelyMK-801, yohimbine, and cocaine, are unaffect-
ed by underlying differences in trait impulsivity. All subjects
showed the same dose response to the pharmacological chal-
lenge; as such, these models may be used without intrinsic and
unknown impulsivity traits confounding the outcome of the
challenge.
In humans and animals, yohimbine can induce transient
anxiety, panic, stress, and mania-like and other hyper-arousal
symptoms (Johnston and File 1989; Southwick et al. 1999;
Stine et al. 2002) that are at least partially mediated directly by
hypothalamic–pituitary–adrenal (HPA) axis activation or indi-
rectly by engaging the extra-hypothalamic stress circuit and
noradrenergic activity. It is conceivable that stress responses,
including those evoked by yohimbine, affect impulse control.
The first evidence for this assumption comes from an experi-
mental medicine study assessing the effect of yohimbine on
impulsivity (Swann et al. 2013). Specifically, a double-blind,
placebo-controlled study in normal healthy volunteers inves-
tigated yohimbine’s effect on performance in the continuous
performance task, the human analogue of the rodent 5-
CSRTT. Yohimbine selectively increased the number and
speed of impulsive responding but had no effect on any other
task parameter. These effects were partially paralleled by an
elevation of noradrenergic but not dopaminergic blood metab-
olites over time, possibly indicating engagement of the extra-
hypothalamic stress circuit. Unfortunately, no self-reported
measures of anxiety were included in this elegant study, which
would have been interesting as patients with high baseline
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Fig. 3 Effect of cocaine (n = 23) on a percentage premature responses, b
percentage accuracy, and c percentage omissions. Panels d–f depict the
results when the group is split into low (n = 10) and high (n = 13)
impulsive subjects. Data are mean ± SD. Asterisks denote a significant
difference between the doses indicated: **p < 0.01 and ***p < 0.001. HI
high impulsive, LI low impulsive
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anxiety, as well as psychiatric patients, such as with post-
traumatic stress disorder, are known to be particularly suscep-
tible to the effects of yohimbine (Mattila et al. 1988;
Southwick et al. 1999). Our data are generally in line with
the observation of trait-dependent drug sensitivity, as HI rats
have a numerically higher number of yohimbine-induced pre-
mature responses compared to LI rats. However, it is impor-
tant to note that the extension of the upward shift in the dose-
response curve in both groups of rats is not different, indicat-
ing that underlying trait impulsivity does not affect the general
outcome of the drug challenge. However, it should be noted
that we cannot fully exclude the possibility that lower doses
than those employed in this study might differentially affect
premature responding in HI and LI rats since yohimbine in-
creased premature responding at the lowest doses tested.
Yohimbine reliably increases impulsivity in rats in a range
of response-inhibition tasks (Mahoney et al. 2016; Schippers
et al. 2016; Sun et al. 2010), some of which are conceptually
analogue to the human Continuous Performance Task, sug-
gesting that a yohimbine challenge can be considered as a tool
for translational studies. Our data are not only generally in line
with these reports but also extend these findings by demon-
strating that yohimbine-induced impulsivity is not affected by
underlying trait impulsivity. This is an important finding, con-
sidering that stratification on traits requires a high number of
subjects, which is often not feasible, both in preclinical studies
as well as exploratory clinical trials. Interestingly, no dissoci-
ation of responding between HI and LI animals has also been
seen when using other noradrenergic agents, namely
guanfacine and atomoxetine (Fernando et al. 2012).
High trait-like impulsivity is a well-known vulnerability
marker/endophenotype for the abuse of stimulants and, poten-
tially, other drugs. An elegant observational study fromErsche
et al. (2010) determining trait impulsivity in siblings of chron-
ic stimulant users evidenced this notion. Siblings who do not
abuse stimulants reported significantly higher levels of trait
impulsivity than age-matched control volunteers. Stimulant-
dependent individuals reported even significantly higher
levels of impulsivity than both their siblings and control vol-
unteers, suggesting that impulsivity can be considered as a
behavioral endophenotype and identifies subjects at risk for
stimulant dependence that may be exacerbated by chronic
drug exposure (Ersche et al. 2010). Additionally, high trait
impulsivity predicts relapse in cocaine- and other stimulant-
dependent individuals (Bosker et al. 2017; Moeller et al.
2001). In rats, high impulsivity predicts escalation of cocaine
self-administration (Belin et al. 2008; Dalley et al. 2007), an
increased propensity for relapse after abstinence, and compul-
sive drug taking (Belin et al. 2008; Economidou et al. 2009).
High impulsivity on the 5-CSRTT is associated with reduced
availability of dopamine D2/3 receptors in the ventral striatum
(Caprioli et al. 2015; Dalley et al. 2007), alterations in den-
dritic spine density, and is selectively and causally determined
by GABA-dependent mechanisms in the nucleus accumbens
core (Caprioli et al. 2014).
Given the well-established link between dopaminergic sig-
naling and impulsivity, it is not surprising that cocaine and
other dopamine-elevating agents are frequently used in rodent
choice reaction time tasks to increase impulsivity in order to
study the effect of putative anti-impulsive drugs (Anastasio
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Fig. 4 Effect ofMK-801 (n = 21) on a percentage premature responses, b
percentage accuracy, and c percentage omissions. Panels d–f depict the
results when the group is split into low (n = 9) and high (n = 12) impulsive
subjects. Data are mean ± SD. Asterisks denote a significant difference
between the doses indicated: *p < 0.05, **p < 0.01, and ***p < 0.001.HI
high impulsive, LI low impulsive
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et al. 2011; Cunningham et al. 2013; Fletcher et al. 2011;
Muschamp et al. 2014). Although dopaminergic drugs are
frequently used as pharmacological challenges to evoke im-
pulsivity, only one previous study determined potential differ-
ential effects in rats stratified for high and low baseline impul-
sivity. No dissociation of responding between HI and LI ani-
mals was identified when using different dopaminergic com-
pounds, namely quinpirole, GBR12909, and methylphenidate
but the D2 receptor agonist sumanirole selectively decreased
premature responding in HI rats (Fernando et al. 2012). In
contrast, baseline-dependent effects of methylphenidate have
been described by Blondeau and Dellu-Hagedorn (2007).
Using a cluster analysis approach, rats trained in the 5-
CSRTT were separated according to their baseline perfor-
mance into four distinct subgroups: efficient, middle, inatten-
tive, and inattentive–impulsive rats. Methylphenidate signifi-
cantly increased premature responses in middle, inattentive,
and inattentive–impulsive rats at highest dose tested, whereas
there was only a trend for increased premature responses in the
efficient subgroup. These data suggest that high-impulsive
rats are more sensitive to methylphenidate. However, in this
study, methylphenidate also had significant effects on re-
sponse and magazine latencies indicating that its effects on
premature responding were not behaviorally selective.
Nevertheless, in the 5-choice continuous performance task,
methylphenidate decreased premature responding in high-
impulsive rats but increased premature responding in low-
impulsive rats (Tomlinson et al. 2014), consistent with the
reported baseline-dependent effects of methylphenidate on
premature responding and D2 receptor availability in the stri-
atum (Caprioli et al. 2015). These studies highlight the impor-
tance of selecting drugs for a pharmacological challenge that
do not differentially affect responding in HI versus LI rats.
This requirement is met by cocaine, as shown by the current
data. Cocaine increases the number of premature responses in
a dose-dependent manner without changing performance ac-
curacy, although a trend for increased omissions and de-
creased response latencies was apparent.
Dysfunctional glutamatergic signaling has been associated
with a number of neuropsychiatric disorders such as schizo-
phrenia (Deakin et al. 1989; Goff and Coyle 2001; Konradi
and Heckers 2003; Lindsley et al. 2006), in which impulse
control deficits are prominent. In experimental animals, system-
ic and local infralimbic administration of the NMDA receptor
antagonists MK-801, PCP, and CPP, and NR2B-selective an-
tagonists have the common effect of increasing impulsivity in
rodents (Agnoli and Carli 2012; Benn and Robinson 2014;
Carli et al. 1983; Fletcher et al. 2011; Greco et al. 2005;
Higgins et al. 2003; Higgins et al. 2016; Isherwood et al.
2015; Murphy et al. 2005; Paine et al. 2007). This effect is at
least partially mediated on the level of the prefrontal cortex, as
indicated by local infusion studies. The neural mechanisms
responsible for the observed behavioral effects are unclear but
may involve modulation of glutamate release in the prefrontal
cortex. Microdialysis studies have shown that NMDA receptor
antagonists cause excessive neuronal firing (Jackson et al.
2004; Lecourtier et al. 2007), leading to increased extracellular
glutamate efflux in the prefrontal cortex of freely moving rats
(Ceglia et al. 2004; Moghaddam et al. 1997; Moghaddam and
Adams 1998). It has thus been hypothesized that altered gluta-
matergic tone in the prefrontal cortex may underpin changes in
impulsivity following administration of an NMDA receptor
antagonist (Isherwood et al. 2015). This hypothesis receives
support from clinical studies indicating a positive correlation
between elevated glutamate levels in the anterior cingulate cor-
tex with ADHD symptomatology and especially hyperactivity
and impulsivity symptoms (Bauer et al. 2016). It has not been
assessed up to this point if differences in glutamatergic signal-
ing might underlie individual differences in trait-like
impulsivity. Previous studies from our group demonstrate that
neither modulation of metabotropic glutamate receptor 4 (group
III) nor metabotropic glutamate receptor 5 (group I) differen-
tially affects premature responses in HI or LI rats (Isherwood
et al. 2015; Isherwood et al. 2017). In this study, the effects of
the NMDA receptor antagonist MK-801 also did not depend on
trait-like baseline impulsivity but resulted in a dose-dependent
increase in the number of premature responses, which was con-
comitant with a dose-dependent decrease in accuracy.
However, it should be noted that we cannot fully exclude the
possibility that lower doses than those employed in the study
might differentially affect premature responding in HI and LI
rats, as MK-801 increased premature responding at the lowest
doses tested. Interestingly, at the highest dose tested, the num-
ber of premature responses appeared to drop in both groups of
rats and was associated with a pronounced increase in omitted
trials, and increased latencies to respond and collect reward in
HI rats. At this higher dose, the NMDA receptor antagonist
tends to impair general task performance, an effect which
may relate to the sedative or locomotor-disrupting effects of this
class of drugs at higher doses (Gilmour et al. 2009; Imre et al.
2006; Isherwood et al. 2015).
The data presented here add to the existing literature,
which shows that specific pharmacological manipulations
of impulsivity on the 5-CSRTT are unaffected by underlying
baseline levels of impulsive responding. Additionally, no
other behavioral variables (accuracy, omissions, etc.) were
differentially affected by any of the drugs tested, adding
further weight to the case that these drugs have no distin-
guishable effects on any aspects of performance in rats se-
lected for extreme premature responding. As such, they can
confidently be used as challenges to enhance premature
responding in rats unselected for pre-existing extreme varia-
tion in impulsivity, saving time and allowing for smaller
group sizes to be used. This is an important prerequisite to
reliably use these challenge models to screen and profile
compounds with putative anti-impulsive characteristics.
Psychopharmacology
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